GIA
CTXR icon

GHP Investment Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

GHP Investment Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-127
Closed -$2.22K – 868
2023
Q3 		$2.22K Hold
127
– – ﹤0.01% 841
2023
Q2 		$3.03K Hold
127
– – ﹤0.01% 804
2023
Q1 		$3.73K Hold
127
– – ﹤0.01% 797
2022
Q4 		$2.52K Hold
127
– – ﹤0.01% 817
2022
Q3 		$4K Hold
127
– – ﹤0.01% 795
2022
Q2 		$3K Hold
127
– – ﹤0.01% 823
2022
Q1 		$6K Buy
+127
New +$5.02K ﹤0.01% 798

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

GHP Investment Advisors's CTXR Position: Q4 2023 in Review

GHP Investment Advisors sold out of Citius Pharmaceuticals (CTXR) in Q4 2023, closing a stake of 127 shares — an estimated $2.22K sold.

GHP Investment Advisors first reported a position in CTXR in Q1 2022 and held it in 7 quarters. The position peaked at $6K in Q1 2022. 74 funds tracked by Wall St. Rank hold CTXR as of Q4 2023.

  • GHP Investment Advisors reported no remaining Citius Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • GHP Investment Advisors sold 127 Citius Pharmaceuticals shares in Q4 2023, an estimated $2.22K.
  • GHP Investment Advisors first reported a position in Citius Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • GHP Investment Advisors's Citius Pharmaceuticals position peaked at $6K in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2023.

Based on GHP Investment Advisors's 13F filing for Q4 2023, filed 26 Jan 2024.